Congress Moves to Combat Nitazenes, Synthetic Opioids 20 Times Stronger Than Fentanyl

A new class of synthetic opioids up to 40 times more potent than fentanyl has prompted bipartisan action in Congress, with lawmakers from both parties introducing legislation this week designed to stop the drugs before they replicate the devastation of America's fentanyl crisis.

Representatives August Pfluger (R-Texas), Michael Baumgartner (R-Washington), and Eugene Vindman (D-Virginia) introduced the House version of the Detection Equipment and Technology Evaluation to Counter the Threat of Nitazenes Act—known as the DETECT Nitazenes Act—on Thursday, March 19. Senator Eric Schmitt (R-Missouri) is leading the companion bill in the Senate, with original co-sponsors including Senators Dave McCormick (R-Pennsylvania), Pete Ricketts (R-Nebraska), Elissa Slotkin (D-Michigan), and Ruben Gallego (D-Arizona).

The legislation comes as the Drug Enforcement Administration added nitazenes to its 2025 National Drug Threat Assessment, a signal that federal law enforcement views the synthetic opioids as an emerging danger. But the threat isn't theoretical. In the United Kingdom, where nitazenes appeared at scale in June 2023, the National Crime Agency has linked the drugs to over 1,000 deaths in just two and a half years—a trajectory that has British officials warning that synthetic opioids now represent "the most significant threat in the ongoing battle against illegal drugs."

Detection Gap

The DETECT Nitazenes Act would direct the Department of Homeland Security's Science and Technology Directorate to coordinate with the DEA to enhance technologies capable of detecting illicit substances at extremely low concentrations. That last detail matters. Unlike fentanyl, which shows up on many standard drug tests, nitazenes often slip through undetected.

"Nitazenes are an emerging class of illicit drugs that pose a serious threat to Americans' health and safety, yet today, these deadly drugs have not received the level of attention necessary to combat them," Pfluger told Blaze News in an exclusive statement. "The DETECT Nitazenes Act will close critical gaps in detection capabilities, support law enforcement efforts, and improve public safety outcomes by enabling faster and more accurate identification of these deadly substances."

That gap has deadly consequences. A September 2025 case in Stevenson Ranch, California illustrates the pattern: a 22-year-old man died after consuming what he believed was Xanax. Toxicology revealed the pill was laced with nitazenes. He had no idea what he was taking. Neither did the routine drug screening systems that might have flagged the contamination.

Nitazenes don't just evade detection—they overwhelm the body. Research published in September 2025 found certain nitazene analogs are over 20 times stronger than fentanyl in receptor binding studies. Some variants are estimated at 1,000 times the potency of morphine. For context, fentanyl is already 50 to 100 times more potent than morphine, and it has killed tens of thousands of Americans annually at the peak of the crisis.

The pharmacology creates a nightmarish scenario for harm reduction. Naloxone—the overdose-reversal medication that has saved countless lives during the fentanyl epidemic—may be less effective against nitazenes' extreme potency. Multiple doses are often required. First responders who arrive expecting to administer one or two nasal sprays of Narcan may find themselves needing four, five, or more, assuming they have enough on hand and the person survives long enough.

Cheaper, Deadlier, Harder to Trace

Senator Schmitt framed nitazenes as an evolution of the opioid crisis, not a departure from it. "Nitazenes are powerful synthetic opioids that are stronger than fentanyl, cheaper to produce, and devastatingly lethal," he said. "These deadly drugs are taking American lives, and we must get smart on them before they devastate communities across Missouri and the nation."

The "cheaper to produce" element is critical. Fentanyl became the dominant illicit opioid in the United States partly because cartels could manufacture it at a fraction of the cost of heroin while delivering far more doses per shipment. Nitazenes follow the same economic logic. If they're even easier or cheaper to synthesize—and early evidence suggests they might be—then the market incentives favor their proliferation.

That's already happening overseas. In Estonia and Latvia, nitazenes were involved in 66% and 42% of overdose deaths respectively in 2023, according to a study published in the journal Addiction in early 2026. Those rates dropped modestly to 43% and 42% in 2024, but the presence remains pervasive. Australia has recorded dozens of nitazene-related deaths, most involving people who had no idea they were exposed. The United Kingdom's thousand deaths came in a nation with a far smaller population and lower baseline opioid use than the United States.

Baumgartner, the Washington Republican co-leading the House bill, emphasized the stealth factor. "Nitazenes are poised to become the next deadly wave of the opioid crisis—cheaper than fentanyl, easy to traffic, and even more lethal," he said. "As cartels quietly mix these drugs into counterfeit pills and powders, too many communities are being put at risk without even knowing it."

The "quietly" part is the threat. Fentanyl's arrival in the U.S. drug supply was catastrophic, but it was also visible. Overdose deaths spiked. Medical examiners flagged the presence of fentanyl in toxicology reports. Public health agencies issued warnings. Harm reduction organizations distributed fentanyl test strips. The crisis was undeniable, even if the response was inadequate.

Nitazenes could follow a different path. If they evade standard detection, if toxicology labs aren't looking for them, if test strips don't catch them, then overdose deaths might climb without anyone understanding why. A person could die, the medical examiner could test for fentanyl and find it, and the death could be attributed to fentanyl—missing the nitazene adulterant that actually caused the fatal respiratory depression.

Legislative Mechanics

The DETECT Nitazenes Act doesn't ban nitazenes outright. The DEA already has authority to temporarily schedule novel synthetic opioids under emergency provisions, and it has done so for specific nitazene analogs like N-pyrrolidino metonitazene and N-pyrrolidino protonitazene. Instead, the legislation focuses on the detection infrastructure that law enforcement, border agents, and harm reduction organizations need to identify the drugs in the first place.

The bill directs resources toward improving field-testing equipment, laboratory analysis, and interagency coordination. That includes supporting the development of portable detection devices that can identify nitazenes at border crossings, in mail facilities, and during traffic stops—places where officers currently rely on presumptive tests that might miss novel synthetics.

It also pushes for research. The Science and Technology Directorate would be tasked with staying ahead of the next generation of synthetic opioids, anticipating what chemists in clandestine labs might produce once nitazenes are widely scheduled. The fentanyl crisis taught a hard lesson: by the time law enforcement catches up to one analog, illicit manufacturers have already moved on to the next.

Representative Vindman, the Virginia Democrat, said he's been focused on nitazenes for months. "For months, I've been working to stop the spread of dangerous nitazenes—highly potent synthetic drugs deemed 'the new fentanyl' that are devastating communities across Virginia and the country," he said. "We cannot wait for this crisis to escalate further. I will continue working to confront the growing threat of nitazenes with the urgency it demands."

The bipartisan, bicameral nature of the legislation suggests it has a real chance of passing, even in a polarized Congress. Opioid legislation has historically enjoyed broad support when it focuses on enforcement, detection, and interdiction rather than treatment funding or harm reduction policies that split along ideological lines.

What Comes Next

If the bill passes, it won't end nitazenes. Legislation doesn't work that way, especially with synthetic drugs. But it could buy time. Better detection means faster public health warnings. It means harm reduction organizations can distribute test strips that actually work. It means medical examiners know what to look for. It means first responders understand they might need more naloxone than usual.

The UK experience offers both a warning and a lesson. The thousand deaths happened despite Britain's harm reduction infrastructure, its national health system, and its relatively lower baseline opioid use compared to the United States. But British officials also mobilized quickly. The National Crime Agency issued public warnings. Health services updated clinical guidance for treating nitazene overdoses. Harm reduction organizations began distributing information about the heightened overdose risk.

In the United States, overdose deaths have finally begun to decline after years of relentless increases. Provisional CDC data showed a nearly 50% drop from the 2023 peak, driven by expanded naloxone access, medication-assisted treatment, harm reduction efforts, and what some researchers believe is a weakening fentanyl supply. That progress is fragile.

Nitazenes could reverse it. A new wave of ultra-potent synthetic opioids entering a drug supply that people have only just begun to navigate safely—with test strips, with naloxone, with medication treatment—could push deaths back up. The DETECT Nitazenes Act is a recognition that the opioid crisis isn't over. It's evolving.

Pfluger put it plainly: "As the risk from synthetic drugs continues to evolve, this legislation ensures that we remain prepared to respond to the next generation of deadly narcotics and protect our communities."

The next generation is already here. Whether the country can respond in time is the question the bill tries to answer.